Regeneron Pharmaceuticals

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1988-01-01

Employees: 13.4K

Market Cap: $132.4B

Website: http://www.regeneron.com

Introduction: Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Clinical Trials

Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma

Phase 4

Recruiting

Conditions: Asthma

Interventions: Drug: dupilumab
Drug: Matching Placebo
Drug: ICS/LABA

First Posted Date: 2024-08-27

Last Posted Date: 2025-04-25

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 250

Registration Number: NCT06572228

Locations: 🇵🇱
Allergy Clinic NZOZ Homeo Medicus, Bialystok, Poland
🇵🇷
Fundacion de Investigacion (FDI) Clinical Research, San Juan, Puerto Rico
🇵🇱
Lekarze Specjaliści Małolepszy i Partnerzy, Wroclaw, Poland

and more 74 locations

A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)

Phase 3

Recruiting

Conditions: Generalized Lipodystrophy

Interventions: Drug: mibavademab

First Posted Date: 2024-08-12

Last Posted Date: 2025-01-22

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 8

Registration Number: NCT06548100

Locations: 🇺🇸
National Institutes of Health, Bethesda, Maryland, United States
🇺🇸
University of Michigan, Ann Arbor, Michigan, United States

A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

Phase 3

Recruiting

Conditions: Age-related Macular Degeneration (AMD)
Geographic Atrophy (GA)

Interventions: Drug: Pozelimab
Drug: Placebo
Drug: Cemdisiran

First Posted Date: 2024-08-07

Last Posted Date: 2025-05-22

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 750

Registration Number: NCT06541704

Locations: 🇺🇸
Associated Retina Consultants, Phoenix, Arizona, United States
🇺🇸
Retina Vitreous Associates Medical Group, Beverly Hills, California, United States
🇺🇸
The Retina Partners, Encino, California, United States

and more 65 locations

Compassionate Use of Evinacumab

Conditions: Pediatric Homozygous Familial Hypercholesterolemia (HoFH)
Severe Hypertriglyceridemia (HTG)
Dysbetalipoproteinemia (DBL)

First Posted Date: 2024-07-15

Last Posted Date: 2025-01-24

Lead Sponsor: Regeneron Pharmaceuticals

Registration Number: NCT06500598

A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)

Phase 3

Active, not recruiting

Conditions: Diabetic Macular Edema
Neovascular Age-Related Macular Degeneration

Interventions: Drug: Aflibercept 8 mg

First Posted Date: 2024-07-09

Last Posted Date: 2025-04-27

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 1118

Registration Number: NCT06491914

Locations: 🇺🇸
Win Retina - Arcadia, Arcadia, California, United States
🇺🇸
California Retina Consultants, Bakersfield, California, United States
🇺🇸
Retina Specialists of Beverly Hills, Beverly Hills, California, United States

and more 52 locations

A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers

Phase 1

Recruiting

Conditions: Primary Peritoneal Carcinoma
Fallopian Tube Cancer
Epithelial Ovarian Cancer

Interventions: Other: 27T51
Drug: Cemiplimab
Drug: Bevacizumab

First Posted Date: 2024-06-21

Last Posted Date: 2025-04-15

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 90

Registration Number: NCT06469281

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
John Theurer Cancer Center Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

and more 1 locations

A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

Phase 2

Recruiting

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Cemiplimab
Drug: Platinum-based chemotherapy
Drug: REGN7075

First Posted Date: 2024-06-18

Last Posted Date: 2025-04-24

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 120

Registration Number: NCT06465329

Locations: 🇫🇷
Montpellier Academic Hospital, Montpellier, France
🇪🇸
Hospital Valdecilla, Santander, Cantabria, Spain
🇫🇷
Centre Hospitalier de la Cote Basque, Bayonne, France

and more 16 locations

A Trial to Learn How Well REGN7508 Works for Preventing Blood Clots After a Knee Replacement in Adult Participants

Phase 2

Completed

Conditions: Venous Thromboembolism

Interventions: Drug: REGN7508
Drug: Enoxaparin

First Posted Date: 2024-06-12

Last Posted Date: 2025-01-30

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 179

Registration Number: NCT06454630

Locations: 🇧🇬
Multi-profile Hospital for Active Treatment Hearth and Brain EAD, Pleven, Bulgaria
🇧🇬
Multiprofile Hospital For Active Treatment Park Hospital Ltd., Plovdiv, Bulgaria
🇭🇺
Budai Irgalmasrendi Korhaz, Budapest, Hungary

and more 11 locations